DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ABLAVAR
All Clinical Trials for ABLAVAR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00375830 | Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases | Completed | Stanford University | Phase 2 | 2006-01-01 | This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer. |
| NCT01135316 | Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR | Completed | Lantheus Medical Imaging | N/A | 2009-10-01 | Phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in USA. Approximately 1,000 patients with moderate-to-severe CKD will be enrolled and followed for up to 24 months. |
| NCT01165892 | Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) | Completed | Lantheus Medical Imaging | N/A | 2011-07-01 | The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI). |
| NCT01165892 | Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) | Completed | Washington University School of Medicine | N/A | 2011-07-01 | The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ABLAVAR
Condition Name
Condition MeSH
Clinical Trial Locations for ABLAVAR
Trials by Country
Clinical Trial Progress for ABLAVAR
Clinical Trial Phase
Clinical Trial Sponsors for ABLAVAR
Sponsor Name
